Maia Biotechnology

MAIA Biotechnology, Inc. is a targeted therapy and immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action, aiming to meaningfully improve and extend the lives of cancer patients. The company's lead program is THIO, a potential first-in-class telomere-targeting cancer drug currently in clinical development for the treatment of telomere-positive cancer patients.